Tenderwize
Zurück zur Suche

Non-exclusive rebate agreement for Aflibercept injectable solution in vial

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Dec 31, 2026 · 127 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Abschl. nicht exkl. Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines OH-Modells zum WS Aflibercept (ATC-Code nach WHO: S01LA05; ausgen. 114,3 mg/ml) als Injektionsl. in einer Durchstechflasche

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

46 / 100

Komplexität

58 / 100

Risikofaktoren

The exact submission process is unclear because the structured data says electronic submission is not allowed, while th...

Demand and purchase volume are explicitly unknown, and no minimum quantity is guaranteed.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Dec 2026
  • Conclusion of non-exclusive rebate agreements for pharmaceutical products containing Aflibercept (ATC S01LA05, excluding 114.3 mg/ml) as an injectable solution in a vial.
  • Open-House participation model: any interested pharmaceutical company may join during the participation period if it meets and accepts the participation conditions.
Vollständige Zusammenfassung anzeigen

This is an Open-House supply arrangement for non-exclusive rebate agreements under §130a(8) SGB V for Aflibercept (ATC S01LA05, excluding 114.3 mg/ml) as an injectable solution in a vial. The procedure is open to all eligible pharmaceutical companies during the participation period, with no individual negotiations and no exclusivity. The notice indicates electronic communication via DTVP, but participation documents must be obtained from the project room after access approval. The contract ends no later than 31.12.2026, and the purchase volume is unknown with no minimum quantity guaranteed.

Risiken

The exact submission process is unclear because the structured data says electronic submission is not allowed, while th...

Demand and purchase volume are explicitly unknown, and no minimum quantity is guaranteed.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal product.
  • The company or its local representative may participate only if it itself qualifies as a pharmaceutical company for the offered product.
  • No Russia-related connection within the meaning of Article 5k of Regulation (EU) No 833/2014, as amended by Regulation (EU) 2022/576, must be declared using the provided...

Auftraggeber

Ort

Erfurt, DEU

Auftraggeberprofil

Profil öffnen

Kennung

DE256878834

Tätigkeit

Health

Lose (1)

LOT-0001

Non-exclusive rebate agreement for Aflibercept injectable solution in vial

Single lot covering non-exclusive rebate agreements for Aflibercept (ATC S01LA05, excluding 114.3 mg/ml) as an injectable solution in a vial. This is an Open-House model with no exclusivity, no individual negotiations, and unknown demand/volume. Place of performance is Dresden, Germany, with performance also referenced for Saxony and Thuringia in the notice text.

SuppliesFrameworkEU fundedElectronic submission

Ort

Dresden, Germany

Dauer

Dec 2025 - Dec 2026

Kategorie

Pharmaceutical products

Frist

Deadline Dec 31, 2026

Vergabedetails

Veröffentlichungsdatum
11 Nov 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
750728-2025

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3